A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Saved in:
| Title: | A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. |
|---|---|
| Authors: | Mayer, E L1 (AUTHOR) emayer@partners.org, DeMichele, A2 (AUTHOR), Rugo, H S3 (AUTHOR), Miller, K4 (AUTHOR), Waks, A G1 (AUTHOR), Come, S E5 (AUTHOR), Mulvey, T6 (AUTHOR), Jeselsohn, R1 (AUTHOR), Overmoyer, B1 (AUTHOR), Guo, H7 (AUTHOR), Barry, W T7 (AUTHOR), Bartlett, C Huang8 (AUTHOR), Koehler, M8 (AUTHOR), Winer, E P1 (AUTHOR), Burstein, H J1 (AUTHOR) |
| Source: | Annals of Oncology. Sep2019, Vol. 30 Issue 9, p1514-1520. 7p. 4 Charts, 1 Graph. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz198 |
